RFK Jr. has announced a plan related to peptides, which may lead to increased access to certain substances. The plan's implications are still being understood, with some outlets suggesting that the FDA may ease restrictions on unproven peptides, while others highlight potential risks and benefits. The move could have significant effects on various stakeholders, including companies involved in the peptide market.